Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

Journal of Virology

Volumn 74, Issue 6, 2000, Pages 2628-2635

  Zur Megede, Jan ^a   Chen, Min Chao ^a   Doe, Barbara ^a   Schaefer, Mary ^a   Greer, Catherine E ^a   Selby, Mark ^a   Otten, Gillis R ^a   Barnett, Susan W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS GENE;

AIDS VACCINES; ANIMALS; CELL LINE, TRANSFORMED; COS CELLS; DNA, VIRAL; FEMALE; GENE EXPRESSION; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV PROTEASE; HIV-1; HUMANS; MACACA MULATTA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEIN PRECURSORS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA; VIRION;

EID: 0034056240     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.6.2628-2635.2000     Document Type: Article

References (32)

1. Barnett, S. W., and M. A. Liu. 1999. DNA vaccines coming of age. Annu. Rep. Med. Chem. 34:149-158.
2. Bertoletti, A., F. Cham, S. McAdam, T. Rostron, S. Rowland-Jones, S. Sabally, T. Corrah, K. Ariyoshi, and H. Whittle. 1998. Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades. J. Virol. 72:2439-2448.
3. Betts, M. R., J. Krowka, C. Santamaria, K. Balsamo, F. Gao, G. Mulundu, C. W. Luo, N. N. Gandu, H. Sheppard, B. H. Hahn, S. Allen, and J. A. Frelinger. 1997. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J. Virol. 71: 8908-8911.
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
5. Budzko, D., D. L. Madden, W. T. London, and J. L. Sever. 1985. Improved separation of rhesus monkey lymphocytes with Percoll. Lab. Investig. 53: 586-588.
6. Chapman, B. S., R. M. Thayer, K. A. Vincent, and N. L. Haigwood. 1991. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19:3979-3986.
7. Clerici, M., and G. Shearer. 1996. Correlates of protection in HIV infection and the progression of HIV infection to AIDS. Immunol. Lett. 51:69-73.
8. Doe, B., and C. Walker. 1996. HIV-1 p24 Gag-specific cytotoxic T-lymphocyte responses in mice. AIDS 10:793-794. (Letter.)
9. Donello, J. E., A. A. Beeche, G. J. Smith III, G. R. Lucero, and T. J. Hope. 1996. The hepatitis B virus posttranscriptional regulatory element is composed of two subelements. J. Virol. 70:4345-4351.
10. Donnelly, J. J., J. B. Ulmer, J. W. Shiver, and M. A. Liu. 1997. DNA vaccines. Annu. Rev. Immunol. 15:617-648.
11. Durali, D., J. Morvan, F. Letourneur, D. Schmitt, N. Guegan, M. Dalod, S. Saragosti, D. Sicard, J. Levy, and E. Gomard. 1998. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J. Virol. 72:3547-3553.
12. Elvin, J., C. Potter, T. Elliott, V. Cerundolo, and A. Townsend. 1993. A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. J. Immunol. Methods 158:161-171.
13. Falk, L., F. Deinhardt, M. Nonoyama, L. G. Wolfe, and C. Bergholz. 1976. Properties of a baboon lymphotropic herpesvirus related to Epstein-Barr virus. Int. J. Cancer 18:798-807.
14. Haas, J., E. Park, and B. Seed. 1996. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr. Biol. 6:315-324.
15. Hentze, M. 1991. Determinants and regulation of cytoplasmic mRNA stability in eukaryotic cells. Biochim. Biophys. Acta 1090:281-292.
16. Huang, J., and T. J. Liang. 1993. A novel hepatitis B virus (HBV) genetic element with Rev response element-like properties that is essential for expression of HBV gene products. Mol. Cell. Biol. 13:7476-7486.
17. Huang, Z. M., and T. S. Yen. 1994. Hepatitis B virus RNA element that facilitates accumulation of surface gene transcripts in the cytoplasm. J. Virol. 68:3193-3199.
18. Huang, Z. M., and T. S. Yen. 1995. Role of the hepatitis B virus posttranscriptional regulatory element in export of intronless transcripts. Mol. Cell. Biol. 15:3864-3869.
19. Karacostas, V., E. J. Wolffe, K. Nagashima, M. A. Gonda, and B. Moss. 1993. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 193:661-671.
20. Klein, M. R., C. A. Vanbaalen, A. M. Holwerda, S. R. K. Garde, R. J. Bende, I. P. M. Keet, J. K. M. Eeftinckschattenkerk, A. D. M. E. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1365-1372.
21. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
22. Kozak, M. 1991. An analysis of vertebrate mRNA sequences: intimations of translational control. J. Cell Biol. 115:887-903.
23. Lynch, J., M. deSouza, M. Robb, L. Markowitz, S. Nitayaphan, C. Sapan, D. Mann, D. Birx, and J. Cox. 1998. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J. Infect. Dis. 178:1040-1046.
24. Moss, P., S. L. Rowland-Jones, P. M. Frodsham, S. McAdam, P. Giangrande, A. J. McMichael, and J. I. Bell. 1995. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc. Natl. Acad. Sci. USA 92:5773-5777.
25. Nasioulas, G., A. S. Zolotukhin, C. Tabernero, L. Solomin, C. P. Cunningham, G. N. Pavlakis, and B. K. Felber. 1994. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J. Virol. 68:2986-2993.
26. Paliard, X., B. Doe, and C. Walker. 1998. The T cell repertoire primed by antiviral vaccination is influenced by self-tolerance. Cell. Immunol. 188:73-79.
27. Rabin, H., R. H. Neubauer, N. J. Woodside, J. L. Cicmanec, W. C. Wallen, B. A. Lapin, V. A. Agrba, L. A. Yakoleva, and G. N. Chuvirov. 1976. Virological studies of baboon (Papio hamadryas) lymphoma: isolation and characterization of foamyviruses. J. Med. Primatol. 5:13-22.
28. Rowland-Jones, S., J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whilby, S. Sabally, A. Gallimore, T. Corrah, et al. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59-64.
29. Schneider, R., M. Campbell, G. Nasioulas, B. K. Felber, and G. N. Pavlakis. 1997. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J. Virol. 71:4892-4903.
30. Schwartz, S., M. Campbell, G. Nasioulas, J. Harrison, B. Felber, and G. Pavlakis. 1992. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J. Virol. 66:7176-7182.
31. Steimer, K. S., J. P. Puma, M. D. Power, M. A. Powers, C. George-Nascimento, J. C. Stephans, J. A. Levy, R. Sanchez-Pescador, P. A. Luciw, and P. J. Barr. 1986. Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria. Virology 150:283-290.
32. Wagner, R., H. Fliessbach, G. Wanner, M. Motz, M. Niedrig, G. Deby, A. von Brunn, and H. Wolf. 1992. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch. Virol. 127:117-137.